nifekalant hydrochloride has been researched along with cisapride in 1 studies
| Studies (nifekalant hydrochloride) | Trials (nifekalant hydrochloride) | Recent Studies (post-2010) (nifekalant hydrochloride) | Studies (cisapride) | Trials (cisapride) | Recent Studies (post-2010) (cisapride) |
|---|---|---|---|---|---|
| 138 | 16 | 38 | 1,554 | 390 | 110 |
| Protein | Taxonomy | nifekalant hydrochloride (IC50) | cisapride (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.767 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 3.37 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.3 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0098 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.5923 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.07 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.1701 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.35 | |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 2.69 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0098 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 3.37 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.3827 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.26 | |
| D | Rattus norvegicus (Norway rat) | 0.0065 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 3.6495 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.7 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0065 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0065 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.083 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0054 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.2597 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 3.6495 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 4.47 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 4.47 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0098 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.384 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.03 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.37 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.03 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.144 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0407 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.535 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2536 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 0.1701 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.994 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, M; Imaizumi, Y; Ohya, S; Yamamura, H | 1 |
1 other study(ies) available for nifekalant hydrochloride and cisapride
| Article | Year |
|---|---|
Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Topics: Action Potentials; Biological Assay; Cell Line; Cisapride; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; HEK293 Cells; High-Throughput Screening Assays; Humans; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Pyridines; Pyrimidinones; Sodium Channels; Terfenadine; Transfection; Verapamil | 2012 |